NovoCure Limited (NVCR)

NMS – Real vaqt narxi. Valyuta: USD

18.31

+0.21 (1.16%)

Yopilishda: May 12, 2026, 4:00 PM EDT

18.31

0.00 (0.00%)

Bozordan keyin: May 12, 2026, 7:38 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

NovoCure Limited (NVCR)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

NovoCure Limited (NVCR)

International Markets and NovoCure (NVCR): A Deep Dive for Investors

NovoCure: Pancreatic Launch Looks Promising, But I'm Not A Believer Yet

NovoCure (NVCR) Reports Q1 Loss, Beats Revenue Estimates

Novocure Reports First Quarter 2026 Financial Results

Novocure to Report First Quarter 2026 Financial Results

NovoCure Tumor Treating Fields Shows Improved Outcomes In Tough Pancreatic Cancer

Novocure Announces Positive Topline Results from Phase 2 PANOVA-4 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Metastatic Pancreatic Cancer

Videolar

No Data

Press-relizlar

Novocure Reports First Quarter 2026 Financial Results

Novocure Announces Positive Topline Results from Phase 2 PANOVA-4 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Metastatic Pancreatic Cancer

Novocure Announces Optune Lua® Receives Reimbursement Approval in Japan for the Treatment of Non-Small Cell Lung Cancer

Novocure Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update

Search stocks

NovoCure Limited (NVCR)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

NovoCure Limited (NVCR)

International Markets and NovoCure (NVCR): A Deep Dive for Investors

NovoCure: Pancreatic Launch Looks Promising, But I'm Not A Believer Yet

NovoCure (NVCR) Reports Q1 Loss, Beats Revenue Estimates

Novocure Reports First Quarter 2026 Financial Results

Novocure to Report First Quarter 2026 Financial Results

NovoCure Tumor Treating Fields Shows Improved Outcomes In Tough Pancreatic Cancer

Novocure Announces Positive Topline Results from Phase 2 PANOVA-4 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Metastatic Pancreatic Cancer

Videolar

No Data

Press-relizlar

Novocure Reports First Quarter 2026 Financial Results

Novocure Announces Positive Topline Results from Phase 2 PANOVA-4 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Metastatic Pancreatic Cancer

Novocure Announces Optune Lua® Receives Reimbursement Approval in Japan for the Treatment of Non-Small Cell Lung Cancer

Novocure Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update